At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Biopsy, and 6 other interventions for Advanced Bladder Urothelial Carcinoma and 23 related conditions. Completed, enrolled 47 participants across 9 sites.
Detailed Summary
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (inoperable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CYT107 is a biological product naturally made by the body that may stimulate the immune system to destroy tumor cells. Giving atezolizumab and CYT107 may work better in treating patients with locally advanced, inoperable, or metastatic urothelial carcinoma compared to atezolizumab alone.
Study Details
Timeline
Interventions
Given IV
Undergo biopsy of tumor
Undergo collection of blood and stool samples
Undergo CT
Given IM
Correlative studies
Undergo MRI
Undergo PET/CT